mAbsolve to present STR technology at PEGS Boston 2022
Our CSO, Ian Wilkinson, will be attending PEGS Boston in the week of 2-6th May. Our antibody silencing ...
Read More mAbsolve to present webinar hosted by The Antibody Society
Our CSO, Ian Wilkinson, will be presenting on the importance of attenuating effector functions in therapeutics antibodies as ...
Read More Absolute Antibody Licenses Novel Fc Silencing Technology from mAbsolve
Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, and mAbsolve, developers of a novel ...
Read More evitria AG announces license of mAbsolve STR technology
evitria AG, the market-leading transient CHO expression service provider, today announces the closing of a license agreement with ...
Read More mAbsolve Quarterly Company Update
This quarter saw our publication on the STR silencing technology accepted and published in PLOS ONE (see here). ...
Read More STR silencing published in PLoS ONE
We are delighted to announce that our novel STR silencing technology has been recently published in the peer ...
Read More mAbsolve Quarterly Company Update
Along with our updated website we are also launching the first edition of our company updates. We intend ...
Read More mAbsolve Launches Updated Website
When the company was founded in December 2019 we were a startup with an interesting technology in the ...
Read More mAbsolve’s STR Patent Application Published
mAbsolve’s international patent application on a novel Fc silencing technology has today been published under application number WO/2021/234402.
Read More - « Previous
- 1
- 2
- 3
- 4
- Next »